FirstHealth of the Carolinas

Clinical Trial Details

Study Title: SWOG 1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Study Type: Interventional
Study Condition: Breast Cancer
Investigator: Dr. Charles Kuzma
Phone: (910) 715-3500
Research Coordinator: Lori DeSpain
Phone: (910) 715-2200
Eligibility Criteria: Women ages 18 and older, diagnosis of breast cancer with positive estrogen (ER)- and/or progesterone-receptor (PR) status, and negative (HER)2 receptor, for whom standard adjuvant endocrine therapy is planned. For additional criteria, call the Research Coordinator or visit the study weblink.
Sponsor Organization: Southwest Oncology Group
Study Rationale: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate, goserelin acetate, leuprolide acetate, anastrozole, letrozole, or exemestane, may fight breast cancer by lowering the amount of estrogen the body makes. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet know whether hormone therapy is more effective when given with or without everolimus in treating breast cancer.
Study Purpose: This randomized phase III trial studies how well giving hormone therapy together with or without everolimus work in treating patients with breast cancer.
Study Link: http://clinicaltrials.gov/show/NCT01674140
   
 
FirstHealth @ Facebook.comFirstHealth @ Twitter.comFirstHealth @ Pinterest.comFirstHealth @ LinkedIn.com
Physicians Employees
Working Together, First in Quality, First in Health
Site MapPrivacy PolicyTerms & ConditionsHelp © FirstHealth of the Carolinas, Inc.